pitavastatin






358 Article(s)
Download
PMID
Title
Journal
Pub. Date
#Total Relationship(s)
1 9891909 Six-month repeated oral toxicity study of NK-104 in rats. J Toxicol Sci 1998 Nov 1
2 10077432 Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile. Biol Pharm Bull 1999 Feb 1
3 10202970 Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1999 Mar 5 1
4 10428299 NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells. Atherosclerosis 1999 Jul 4
5 11325797 NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells. Br J Pharmacol 2001 May 4
6 11480454 Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 2000 4
7 11554731 Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun 2001 Sep 21 4
8 11779144 Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun 2002 Jan 11 3
9 11900720 Managing dyslipidemia in the high-risk patient. Am J Cardiol 2002 Mar 7 1
10 11996957 A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 2002 Jun 1
11 12040967 Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung 2002 1
12 12047044 Inhibition of migration and proliferation of rat vascular smooth muscle cells by a new HMG-CoA reductase inhibitor, pitavastatin. Hypertens Res 2002 Mar 5
13 12191589 Triglyceride-lowering effect of pitavastatin [corrected] in a rat model of postprandial lipemia. Eur J Pharmacol 2002 May 24 3
14 12231401 HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci 2002 Oct 4 1
15 12442637 Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans. Arzneimittelforschung 2002 1
16 12486415 Management of dyslipidemia in the high-risk patient. Am Heart J 2002 Dec 1
17 12498010 Pitavastatin Nissan/Kowa Yakuhin/Novartis/Sankyo. Curr Opin Investig Drugs 2002 Sep 2
18 12519692 Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica 2003 Jan 6
19 12621163 Pitavastatin inhibits vascular smooth muscle cell proliferation by inactivating extracellular signal-regulated kinases 1/2. J Atheroscler Thromb 2003 8
20 12705169 Triglyceride-lowering effect of pitavastatin in a guinea pig model of postprandial lipemia. Arzneimittelforschung 2003 7
21 12740485 Plaque-stabilizing effect of pitavastatin in Watanabe heritable hyperlipidemic (WHHL) rabbits. J Atheroscler Thromb 2003 4
22 12743630 Pitavastatin (NK-104), a new HMG-CoA reductase inhibitor. Drugs Today (Barc) 2001 Sep 2
23 12880107 Pitavastatin ameliorates severe hepatic steatosis in aromatase-deficient (Ar-/-) mice. Lipids 2003 May 1
24 12938153 Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J Cell Biochem 2003 Sep 1 12
25 14733921 Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004 Feb 6 2
26 14969717 Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia. Life Sci 2004 Mar 12 1
27 15049129 The novel HMG-CoA reductase inhibitor, Pitavastatin, induces a protective action in vascular endothelial cells through the production of nitric oxide (NO). Yakugaku Zasshi 2004 Mar 4
28 15118259 [Pharmacological and pharmacokinetic features and clinical effects of pitavastatin (Livalo Tablet)]. Nihon Yakurigaku Zasshi 2004 May 5
29 15159445 Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004 Oct 13
30 15166180 Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension 2004 Jun 1
31 15167274 Pitavastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, blocks vascular smooth muscle cell populated-collagen lattice contraction. J Cardiovasc Pharmacol 2004 Jun 1
32 15234191 MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway. Life Sci 2004 Jul 30 10
33 15244070 Pitavastatin enhances the anti-fibrogenesis effects of candesartan, an angiotensin II receptor blocker, on CCl4-induced liver fibrosis in rats. J UOEH 2004 Jun 1 2
34 15283301 Effect of gemfibrozil on the metabolism of pitavastatin--determining the best animal model for human CYP and UGT activities. Drug Metabol Drug Interact 2004 7
35 15292460 Involvement of multiple transporters in the efflux of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors across the blood-brain barrier. J Pharmacol Exp Ther 2004 Dec 3
36 15327760 Protective effect of pitavastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, on ischemia-induced neuronal damage. Neurol Res 2004 Sep 7
37 15329062 Effect of pitavastatin against expression of S100beta protein in the gerbil hippocampus after transient cerebral ischaemia. Acta Physiol Scand 2004 Sep 4
38 15338328 Pitavastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, reduces hippocampal damage after transient cerebral ischemia in gerbils. J Neural Transm (Vienna) 2004 Sep 4
39 15344842 Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase. Arzneimittelforschung 2004 7
40 15358158 Pitavastatin increases ABCA1-mediated lipid efflux from Fu5AH rat hepatoma cells. Biochem Biophys Res Commun 2004 Aug 27 5
41 15380447 A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits. Atherosclerosis 2004 Oct 2
42 15474503 Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun 2004 Nov 12 10
43 15485693 HMG-CoA reductase inhibitors up-regulate anti-aging klotho mRNA via RhoA inactivation in IMCD3 cells. Cardiovasc Res 2004 Nov 1 1
44 15502389 Pitavastatin, a potent hydroxymethylglutaryl coenzyme a reductase inhibitor, increases cholesterol 7 alpha-hydroxylase gene expression in HepG2 cells. Circ J 2004 Nov 9
45 15502390 Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor. Circ J 2004 Nov 1
46 15557368 Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104). Circulation 2004 Nov 30 5
47 15591219 Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through ApoB48 receptor-dependent mechanism. Arterioscler Thromb Vasc Biol 2005 Feb 3
48 15618696 Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase--effect of cMOAT deficiency on hepatobiliary excretion in rats and of mdr1a/b gene disruption on tissue distribution in mice. Drug Metab Pharmacokinet 2002 3
49 15618742 Uptake mechanism of pitavastatin, a new inhibitor of HMG-CoA reductase, in rat hepatocytes. Drug Metab Pharmacokinet 2003 1
50 15690306 Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism 2005 Feb 5